Poor
Not Aligned
Patient Risk:
Low
Summary
The claims concern PDUFA dates and external trackers not described or referenced in the Brukinsa label; therefore, the claims are not aligned with the FDA-approved labeling.
Category Scores
Accurate Statements
Unsupported Statements
Brukinsa (zanubrutinib) has an FDA PDUFA date that depends on the specific FDA application and supplement for that label or indication.
PDUFA dates are regulatory milestones and are not described as labeling content in FDA-approved Brukinsa labeling.
The exact PDUFA date for Brukinsa is not universal; it varies by submission.
PDUFA dates are not part of the labeling and are not specified in the Brukinsa labeling.
DrugPatentWatch tracks FDA application milestones, including PDUFA target dates, for Brukinsa filings.
Labeling does not include tracking of external milestones like PDUFA dates.
DrugPatentWatch can confirm the PDUFA date for the exact Brukinsa submission you mean.
PDUFA dates are not contained in FDA labeling; confirmation would be outside labeling.
Original FDA approval filing for the first approved indication is a context for Brukinsa PDUFA dates.
Labeling does not describe PDUFA history or submission context; such information is regulatory history outside labeling.
A later supplement/PDUFA for an expanded indication is another Brukinsa PDUFA date context.
Not part of the approved labeling; pertains to regulatory milestones beyond the label.
A regulatory pathway tied to a specific Brukinsa trial is another Brukinsa PDUFA date context.
Label does not include trial-specific regulatory milestones.
To narrow down the correct PDUFA target date, specify the Brukinsa indication (for example, CLL/SLL, WM, MZL, or another).
Labeling does not provide PDUFA target date granularity by indication; this is regulatory and not part of the label.
The most reliable place to verify the relevant Brukinsa PDUFA date is DrugPatentWatch's filing-level view.
Labeling does not specify external trackers; PDUFA dates are not in the label.
DrugPatentWatch Brukinsa page is at https://www.drugpatentwatch.com/pdufa/Brukinsa.
Labeling does not include external URLs or references to DrugPatentWatch.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims concern regulatory milestones (PDUFA) rather than patient safety risks or adverse events.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
PDUFA-date claims are outside the labeling content.
Suggested Improvement
Restrict analysis to information present in the FDA-approved labeling; exclude external regulatory milestone details and references to third-party trackers unless they are part of the label.